XOMA

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

03/19 04:05 pm

XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

03/08 08:30 am

XOMA to Present at Upcoming Investor Conferences in March

02/28 08:30 am

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

02/16 09:00 am

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

01/18 09:30 am

FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

01/11 05:05 pm

XOMA Announces Stock Repurchase Program of up to $50 Million

01/02 08:30 am

XOMA Declares Quarterly Preferred Stock Dividends

12/20 08:30 am

I'm Buying Preferred Stocks Hand Over Fist

12/15 09:30 am

XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value

11/07 08:30 am

XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

10/31 07:30 am

Ride The Royalty Ripple To Riches Like Charlie Munger

10/06 07:35 am

XOMA Declares Quarterly Preferred Stock Dividends

09/25 07:30 am

Xoma (XOMA) Moves 7.7% Higher: Will This Strength Last?

09/18 12:41 pm

XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference

09/06 07:30 am

XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy

08/08 07:30 am

Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates

08/02 06:15 pm

XOMA Added to the Russell 2000® and Russell 3000® Indexes

06/23 06:14 pm

Arimoclomol and Aldoxorubicin Acquisition to Bolster XOMA's Revenue Growth: Analyst

06/22 03:09 pm

XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset

06/22 07:30 am

XOMA Declares Quarterly Preferred Stock Dividends

06/20 07:30 am

XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy

05/09 07:30 am

Strength Seen in Vertex (VRTX): Can Its 5.0% Jump Turn into More Strength?

04/28 03:28 am

XOMA to Present at H.C. Wainwright BioConnect Investor Conference

04/26 07:30 am

XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio

03/30 07:30 am

XOMA Declares Quarterly Preferred Stock Dividends

03/21 07:30 am

XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization Strategy

03/09 08:30 am

XOMA to Present at 43rd Annual Cowen Health Care Conference

02/28 08:30 am

XOMA Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01/06 08:00 pm

New Executive Leadership Team Appointed to Accelerate XOMA’s Differentiated Royalty Monetization Strategy

01/04 08:30 am

XOMA Declares Quarterly Preferred Stock Dividends

12/22 08:30 am

XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon

11/22 08:01 am

XOMA Declares Quarterly Preferred Stock Dividends

09/21 07:30 am

Starbucks And 3 Other Stock Insiders Are Buying

09/19 10:57 am

XOMA to Present at H.C. Wainwright 24th Annual Global Investment Conference

09/07 07:30 am

Xoma (XOMA) Reports Q2 Loss, Misses Revenue Estimates

08/04 10:45 am

XOMA Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Events

08/04 07:30 am

XOMA Declares Quarterly Preferred Stock Dividends

06/20 07:30 am

XOMA to Present at H.C. Wainwright Global Investment Conference

05/17 04:05 pm

Xoma (XOMA) Reports Q1 Loss, Misses Revenue Estimates

05/05 08:55 am

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Lags Revenue Estimates

05/03 08:15 am

XOMA Declares Quarterly Preferred Stock Dividends

03/21 07:30 am

XOMA to Present at the 42nd Annual Cowen Health Care Conference

03/01 08:30 am

XOMA to Present at Aegis Capital Corp Investor Conference

02/17 08:30 am

XOMA Declares Quarterly Preferred Stock Dividends

12/23 08:30 am

XOMA to Present at Upcoming Investor Conferences

12/21 08:30 am

XOMA Announces Evolution of Company Leadership and Succession Planning

12/16 08:30 am

Xoma (XOMA) Reports Q3 Loss, Misses Revenue Estimates

11/04 10:15 am

XOMA Earns $35 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Clinical Study in Metastatic Pancreatic Cancer

11/04 07:40 am

XOMA Reports Third Quarter 2021 Financial Results and Highlights Recent Operational Events

11/04 07:30 am